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Abstract 
This study was performed  to detect any behavioral or brain histological changes may be  related to oseltamivir 
.phosphate. .administration.in.mice pups.The neurotoxic effects of oseltamivir phosphate in mice pups  was 
evaluated  by the  results  of selected  neurobehavioral tests and histopathological lesions that observed  in the 
brains of treated animals by  direct   daily oral drug administration  for  the last fourteen days of lactation period 
,the study began when pups reached 7 days of  age. The experimental groups consist of three treated groups 
T1,T2,T3 were given  the dose 2.5, 7.5 and 25 mg/kg B.W of oseltamivir phosphate orderly while control group 
treated with distilled water. The results of performed neurobehavioral test which including  open field test, head 
pocking , cleft avoidance ,swimming rank, righting reflex  and negative geotaxis tests indicated clearly presence 
of  behavioral changes of treated animals and this results are supported by histological lesions of brain which 
observed a dose dependent manner effect, even at therapeutic dose.These   results probably were attributed to the 
change of the level of CNS neurotransmitters  or due to brain lesions may be caused by the drug which may 
affect the release of these neurotransmitters accordingly with  oseltamivr phosphate dose.  
Keywords:oseltamivir phosphate, neurobehavioral ,neurotransmitters, toxic effect  
 
1. Introduction.  
 Influenza is a highly contagious, acute febrile respiratory infection caused by the influenza virus. Cases typically 
occur in a seasonal pattern, with localized epidemics during  winter months. (1).
 
Oseltamivir 
is,,an.orally,.administered anti-influenza agent of the neuraminidase inhibitor class. The ethyl ester prodrug 
oseltamivir is delivered orally as a phosphate salt and converted by hepatic esterases to the active metabolite 
oseltamivir carboxylate (OC) (2).OC specifically binds and inhibits the influenza virus neuraminidase enzyme that 
is essential for viral replication (3).In this way, oseltamivir limits the spread of influenza virus subtypes A and B 
within the infected host .When ,used,. as ,treatment, oseltamivir. ,reduces, .the., severity .and ,duration .,of, 
symptoms  (4),while ,prophylactic administration prevents their onset(5) . In recent years, abnormal or delirious 
behaviors have been reported with a low incidence in young individuals with influenza who were receiving 
oseltamivir (6). Cases arose most commonly in Japan but were also observed in Taiwan, Hong Kong, North 
America, Europe, and Australia. No causative association could be demonstrated, and similar events were also 
reported in the absence of oseltamivir (7). The relationship between abnormal behavior and oseltamivir medication 
remains an open question .Lactogenic  study was performed to detect the neurotoxic effect of oseltamivir 
phosphate in mice pups suckling from nursing mice dosed with oseltamivir phosphate daily for fourteen days  
,these suckling  pups showed neurotoxic symptoms (8) .In this study  we tried to explore the probable neurotoxic 
effects in 7 days aged mice pups  directly dosed with oseltamivir phosphate in ordered to record for the first time 
such nurotoxic effects. 
 
2.Materials and Methods 
2.1.the drug 
Oseltamivire phosphate (flufly) ® 75 mg produced by Julphar Pharmaceutical Industries,Ras   AL  -
Khaimah,UAE. 
2.2.Neurobehavioral Tests Apperatuses :Specific apperatus were used to performe neurobehavioral     tests in 
isolated room . 
2.3.Oeltamivir phosphate dosage and dose 
 Oseltamivir phosphate stock solution (1mg/ml) was obtained by dissolving 1capsule of 75mg of oseltamivir 
phosphate in 75ml distilled water. then 1 ml of stock was diluted with 7ml of distilled water to prepare the 
concentration of 0.125mg/ml .administrated  with dose volume 0.1ml/5gm.BW in therapeutic dose of 
2.5mg/kg.BW to T1,while  6 ml of stock solution was diluted with 10 ml distilled water to prepare the  
concentration  0.375mg/ml  administrated toT2 in  three folds of  the therapeutic dose 7.5mg/kg.BW at dose 
volume  0.1ml/5 gm .BW ,the 10 folds dose was prepared by dissolving 1capsule 75 mg of oseltamivir phosphate 
in 60ml  of distilled water to prepare the  concentration  of 1.25mg/ml with dose volume of  0.1ml/5gm.BW in 
10 folds of therapeutic dose 25mg/kg BW.  five  pups of control group were given  distilled water for 14 days. 
The mice pups were dosed  daily by using specific plastic gevag  needle.  
2.4.The Animals 
Four recently parturated pups mice , each delivered 6-8 mice pups from each  5 pups were allocated to one 
treated group that dosed at age 7 days when the pups body weight 3-5 gm  in order to study the neurobehavioral 
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effects of oseltamivire phosphate at different lactating and post treatment periods .The animals and their pups 
were procured from the animal house of the College of Veterinary Medicine /Baghdad University under ethical 
rules and huminity of the university.The animals were maintained in an air-conditioned  room  22±3 ºC with 
about (14 /10) Hours(Light/Dark) cycle standard, pilliets ,and.. water.. provided. .ad.libitum (9). 
2.5.Experimental Design 
seven days after parturition  total number of (20)pups of  albino mice were divided equally into four 
experimental groups consist of  one control group dosed daily with distilled water  .While  three treatment 
groups T1,T2 and T3 similarly  divided  and  used to detect neurotoxic effect of oseltamivir phosphate through 
direct administration of oseltamivir phosphate to experimental pups during the last 14 days of lactation period   
when Blood Brain Barrier(BBB) is not fully mature 7-21 days of age ,and  at 7th  day after stoppage of treatment 
when  BBB is fully mature after 28 day of age ( 10). 
pups of  experimental groups (T1,T2,T3and C) were tested for the following parameters:  
  1. Neurobehavioral tests to detect abnormal behavior in the 14thday of age (7 days of  treatment ) ,21th day of 
age ( 14 days of treatment )  and 28th day of   age (7th day post treatment) which included  the  following tests :-  
Open field test , Head pocking test, Negative geotaxis test, Righting reflex test, Cleft avoidance test, Swimming 
rank test. 
2.  Histopathological lesion of brain. 
2.6.NEUROBEHAVIORAL TESTS:- 
1.  Open field test/ 3 minutes :- The test evaluates the general locomotor activity, exploration (squares crossed 
by four legs of animal forward & backward ) , and also including frequency of defecation & urination ( 
Autonomic nervous impressed ) .Each mouse was placed in the center of arena of open field apparatus and the 
number of squares crossed was counted, rearing, fecal boluses and urine pools during (3) minutes . Arena was 
cleaned after each try  (11). apparatus was used  according to specification design in which  box at diamensions  
35x35x25 cm the arena divided into 25 equal squar 7x7cm² each as shown in. The arena used to perform open 
field tests for mice locomotor activity. 
2. Negative Geotaxis/ 60 seconds : This test reflects vestibular function ,  neuromotor performance and 
coordination , the angle slope apparatus is 45º ,we placed mouse with the head was placed in down position on 
the inclined surface , Time that the mouse needed for completing  180º - turn was regestirated, the  maximum 
time allowed was 60 seconds ( 12 ). Specific apparatus was used , it  consist of  a wooden slope with  an angle 
45°. 
3. Head Pocking Test/3minutes: - This test determines the degree of cognitive function of animal exploration 
of environment  by  registration the frequency of head entrances into pores during (3) minutes (13). :- performed 
by using specific device with  eight punchers in plastic  Circular plate (30 cm diameter and 10 cm highness) 
4.Righting Reflex Test : tested pups were kept laying on back . The time needed for adjusting posture recorded ; 
this test evaluates the motor activity of pups  (14 ). Formica table with average height  9 cm , used to perform  
righting reflex test and also to perform cleft avoidance that reflects the   proper reflex. 
4. Cleft Avoidance Test : This was  performed  by putting pups close to cleft of table with highness more than 
( 9 ) cm , the time needed by pups for turned of were recorded , this test is useful for detection of the proper 
reflexes  (14). 
5. Swimming Rank Test/10 seconds :- This test reflects  the integration of  brain function by monitoring  each 
animal  kept  for (10)  seconds  for swimming in a pool containing warm water  (30C º)  and  evaluated by grades 
of swimming rank as follows as shown in Fig(11)( 15 ) and ( 16). 
  - Grade (0): When the nose is under the plane of water,Grade (1): The nose with plane or above water,Grade 
(2): The nose and crown with, or above the plane of water   while the  ears are under,Grade (3): As in grade (2) 
but the plane of water at the mid of hears,Grade (4): As in grade (3) but the plane of water under the ears 
3.7.Statistical analysis:Statistical analysis of data was performed on the basis of Two-Way  Analysis of 
Variance (ANOVA) using a significant level of (P<0.01). Specific group differences were determined using 
least significant differences (LSD) as described by (17). 
 
 RESULTS 
3.1.NEUROBEHAVIORAL TESTS: 
 The results listed in table (1) revealed  according to the tested behavior that T1 group  pups at 7th day of 
treatment  showed  significant(P<0.01)  increase in locomoter activity and exploration , defect in proper reflex ( 
table 1.A and E),while T2 group showed a defect in motor function  ,proper reflex  and brain integration 
(table1.D,E,F), while T3group showed a decrease in locomotor activity and exploration table (1.A), defect in 
vestibular function interfere with short term memory  , proper reflex , motor function  table and brain integration 
(table1,A,C,E,D,F) .At the 14th day of treatment T1 showed an increase in autonomic nervous system activity 
(frequency of fecal bolus)  and defect in motor function (table 1.A and D), while T2and T3 showed a decrease in  
autonomic nervous system activity (frequency of fecal bolus) ,defect in proper reflex  ,motor function  and brain 
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integration (table 1.A,E,D,F), but only T3 showed a decrease in locomotor activity and exploration , defect in 
degree of cognitive function of exploration (table1.A and B). At 7 day post treatment T1,T2and T3 showed 
defect in degree of cognitive function of  exploration ,motor function (table 1.B and D), only T1showed a 
decrease in locomotor activity and exploration (table 1.A), while only T2 and T3 showed a decrease in 
autonomic nervous system activity (frequency of fecal bolus) and a defect in proper  reflex (table 1.A and E). 
 
Table (1)(A,B,C,D,E,F)Selected neurobehavioral tests of mice  pups dosed directly and orally with three 
different doses of oseltamivir phosphate  during lactation period. 
(A) Open field/3 minutes 
7 days after   treatment 
termination 
M±SE 
14 days of treatment 
M±SE 
7 days of treatment 
M±SE 
Period 
Group 
n=5 pups 
1.Number of crossed squares/3 minutes 
AB 125±14.1 a  
             
A 143.2±5.8 a  
                
B 14±1.4 b 
 
C(D.W)  
B 103.20±7.6 b 
               
A 145.60±4.044 a 
              
A18.8±1.0 c 
                  
 
T1(2.5mg/kg) 
A 133.60±0.1 b 
             
A 144.4.  ± 8.0 a 
               
B13±1.3 c 
             
 
T2(7.5mg/kg) 
A 135.60±7.7 a 
               
B 13±5.7 b 
              
C 3.8±1.1 b T3(25mg/kg) 
  
   2.Frequency of fecal bolus/3minutes 
                            A 2.8±0.2  a                                                       B 1.6±0.2 b                   A 0.2±0.1c 
 
C(D.W) 
A 4±0.3 a  A 3.6±0.5 a 
 
A 0.2+±0.1b 
 
T1(2.5mg/kg)  
B 0.8±0.3 a 
 
C 0.60±0.2 a 
 
A 0.2±0.1 a 
 
T2(7.5mg/kg)  
 B 0.2±0.1 a 
 
 C 0.2±0.1 a 
 
A 0.2±0.1 a 
 
T3(25mg/kg) 
  3. Frequency of urination/3minutes 
A 0.2±0.1 a A0.2±0.1 a 
               
A0.2±0.1 a C(D.W) 
 
A 0.2±0.1 a 
 
0.2±0.1 a 
 
A0.2±0.1 a T1(2.5mg/kg)  
A 0.2±0.1 a 
 
A0.2±0.1a  A0.2±0.1 a 
 
T2(7.5mg/kg) 
 
A0.2±0.1 a 
 
A 0.2±0.1 a 
 
A0.2±0.1a  
 
T3(25mg/kg)  
 
 
TESTs (B)Head pocking/3minute  (C)Negative geotaxis/60 seconds  (D) Righting Reflex test/seconds 
Period      
    
Group       
n=5pups    
              
14 days of  
treatment 
M±SE  
7 days 
post  
treatment    
M±SE 
7 days of 
treatment 
M±SE  
14 days of 
treatment  
M±SE 
7 days stop  
treatment   
M±SE   
7 days of 
treatment 
M±SE 
14 days 
of 
treatme
nt 
M±SE 
7 days after  
stop 
treatment  
M±SE 
C 
D.W 
6.60±0.7 
A           a 
11.6±1.3 
A            a 
4.2±0.2 
B           a  
3.4±0.4 
A                a  
3.2±0.9  
A           a  
21±0.6 
B             a 
16.4±0.6 
B           b 
15.6±0.2 
B         b 
T1(2.5mg/k
g) 
6.80±0.7 
A             a 
3.8±0.3 
B           b 
4.60±0.6 
B             a  
4.4±1.6 
A                a  
5±0.31  
A            a 
23.20±1.2        
B         a 
23.20±0.7 
A              
a 
18.8±0.2 
A           b 
T2(7.5mg/k
g) 
5.4±0.6 
A              a 
3.80±0.4 
B            b 
6.20±0.3 
AB         a  
5.4±1.2 
A                
ab  
4.2±0.7 
A            b  
100.4+±27.
2 
A         a 
23.40±0.6 
A           b 
19.20±0.7 
A          b 
(25mg/kg) 
T3  
0.2±0.1 
B              a  
1.6±1.1 
C          a  
8.20±0.8 
A        a  
5.4±0.7 
A          b  
4.0±0.3 
A           b  
101.80±19.
8 
A          a 
25±0.6 
A          b 
20.66±1.2 
A           c 
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Different  small letters represent  significant differences   within groups(P≤0.01) 
-Different  capital  letters  represent  significant differences  between  groups (P≤0.01) 
M±SE=mean+ standard error 
 
Histopathological  lesions 3.2. 
 Brain 
  1.Control group:- Organs of the  control group showed no histopathological changes (Fig.1). 
2.Therapeutic dose (group T1):-Cerebrum :Congestion of cerebral  blood vessels with perivascular and  
perineuronal edema and shrinkage of neurons (Fig.2). Cerebellum:showed edema between molecular and 
granular layer with degeneration of many purkinji cells  and complete dissolution of the others (Fig.3). 
3.Three folds dose (group T2):-In addition to  histopathological changes seen in therapeutic dose there is severe 
hemorrhage in meninges (Fig.4) with mild hemorrhage in the cerebellum (Fig.5) . 
 
4.Ten folds dose group( T3) :-The cerebrum showed multiple areas of focal  gliosis (Fig.6) .Other areas showed 
spongiosis (Fig.7).In addition to cerebral vascular inflammation and necrosis (Fig.8). 
                                    
  
 
                                     
 
 
Test     (E) Cleft avoidance/minutes (F) Swimming rank test 
Period  
Group  
 n=5  pup         
7 days of treatment 
M±SE  
14 days of 
treatment  
M±SE  
7 days after  stop 
treatment  
M±SE  
7 days of 
treatment 
M±SE  
14 days of 
treatment  
M±SE 
7 days after stop  
treatment  
          M±SE 
 C 
D.W 
B1.4±0.244 a 
 
B 0.8±0.2 a 
 
B 0.8±0.2 a 
 
A 3.8±0.2 a 
 
A 3.8±0.2 a 
 
A 3.8±0.2 a  
 
T1(2.5mg/kg)  A 2.60±0.244 a  AB 1.4±0.244 
b 
AB1.4±0.244 b 
 
A 3.20±0.2 
a 
A 3.8±0.2 a A 3.8±0.2 a 
T2(7.5mg/kg)  A 3.2±.0.734 a 
 
A 1.6±0.244 b 
 
A 1.6±0.244 b 
 
B 2.2±0.2 c 
 
B 2.8±0.2 b 
 
A 3.8±0.2 a  
 
T3(25mg/kg) 
  
 A 3.4±0.244 a 
 
 A 1.8±0.374 b 
 
A 1.8±0.48 b 
 
B 1.8±0.2 c 
 
B 2.8±0.2 b 
 
A 3.2±0.2 a 
 
Fig (1): Histopathological section of brain of mouse pup 
of ( control group)  treated with distilled water  for 14 day  
shows  normal histological structure (H&Ex100) 
 
Fig(2) :Histipathological section of  cerebrum of brain of mouse pup of  ( T1) 
treated with  2.5 mg/kg BW/day for 14 day shows  perivascular(         )   and 
perinural (          )  odema with shrinking of neurons(H&Ex400) .                 
Fig (3): Histopathological section of  cerebellum of brain o f mouse  pup of( 
T1) treated with  2.5 mg/kg BW/day of  oseltamivir phosphate for 14 day 
shows  edema between molecular and granular layer with degeneration of 
many purkinji cells  and complete dissolution of the others(              )  
(H&Ex400) . 
 
Fig(4): Histopathological section of  brain  of  mouse pup of (T2) treated 
with  7.5 mg/kg BW/day of oseltamivir phosphate for 14 day  shows  severe 
hemorrhage in meninges (          )     (H&Ex400)                                
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Discussion 
       Primarily in this study it was thought  that OP and/or its metabolite oseltamivir carboxylate( OC) has the  
ability to penetrate blood brain barrier(BBB)  just like many drugs ,at time when BBB is not fully mature in early 
neonate life during lactation period. There is growing interest in the penetration of oseltamivir and its active 
form into the brain(18) .It was reported that in developing mice BBB maturation is complete around the third 
postnatal week.(10). Because of  this  probable penetration   that may be occured   during lactation period may be 
interfere with CNS neurotransmitters . Neurotransmitters are  chemical signals  in by which communications 
between nerve cells –nerve cells  and effector organs are occurs .CNS neurotransmitters divided in to 3 groups 
(biogenic amines , neuropaptide and amino acids)a. biogenic amines including Ach which is excitatory 
responsible for (arousal ,short term memory ,learning and movements ),b .norepinehprin which is excitatory 
involved in ( arousal ,wakefulness, mood and cardiovascular regulation), c.dopamin which is excitatory involved 
in emotion reward system and motor function )d. serotonin which is excitatory /inhibitory involved in feeding 
behavior ,control of body temperature  modulation of sensory pathways including nociception (stimulation of 
pain nerve sensor)regulation of mood and emotion and sleep /wakefulness)(19) ,so any defect in production 
,storage and release of these neurotransmitters  cause defect in the functions that these neutronsmitters  are 
involoved with.It was reported during a study performed on  wibester rats  , when these rats received  OP at dose 
25 and 100 mg/kg.BW I/P the result indicated that an increase extracellular dopamine  significantly from pre-
administration level in prefrontal cortex (PFC) (20).While in this current study the results of open field test 
indicated that the significant increase in movement(crossed squares /3minutes )and (frequency of fecal bolus/3 
minutes )recorded in T1 pups group was possibly due to marked CNS  and autonomic cholinergic effect caused 
by drug at therapeutic dose, while their significant decrease in higher doses (T2,T3) was inhibitory CNS either 
due to opposite effect ( dopaminergic or other CNS neurotransmitters  like serotonin) or may be due to  brain 
damage that  more noticed histologicaly  in higher doses of OP or  may be due to that OP and/or  its metabolite 
that may be peripherally  have  muscarinic  receptors  which change gut motility that affect fecal frequency.The 
phenotype of mutant mice with impairments in dopamine or norepinephrine biosynthesis exhibit severe motor 
dysfunctions characterized by a reduction in spontaneous locomotion and cataleptic behavior, and defects in 
drug-induced hyperactivity at the juvenile stage (21). It was showed that activation or inhibition of 
neurotransmitters cause significant alteration in performance of human and laboratory animals on variety of 
Fig(5): Histopathological section of  cerebellum  of mouse  pup of (T2) treated with 
7.5 mg/kg BW/day of oseltamivir phosphate for 14 day shows  mild hemorrhage(           
)  (H&Ex400). 
Fig(6): Histopathological section of  cerebrum  of mouse pup of  
(T3) treated with  25 mg/kg BW/day of oseltamivir phosphate  
for 14 day shows  focal  gliosis   (                  )    (H&Ex400)                         
Fig(7): Histopathological section of  cerebrum  of mouse pups of 
(T3)  treated with25 mg/kg BW/day of oseltamivir phosphate for 
14 day  shows spongiosis (          )  (H&Ex400) 
 
Fig(8):Histopathological section of   cerebrum of  mouse pup of  (T3) 
treated  with  25 mg/kg BW/day of oseltamivir phosphate  for 14 day 
shows cerebral vascular vasculitis  and  necrosis (               )  (H&Ex400). 
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tasks of spatial attention (22) and working memory(23). Based largely on the main pharmacological properties of 
serotonin and noradrenalin uptake inhibitors used for the treatment of depression, deficient extracellular levels of 
these monoamines have long been hypothesized to play a key role in the development of the core symptoms of 
this disorder (24),also an indirect evidence from cat, rat and mouse preparations suggests that glutamenergic 
projections contribute to the initiation of locomotion since application of glutamatergic antagonists at the spinal 
cord level block locomotor activity under certain conditions (25).The  probable change in  the levels of 
neurotransmitters might explain the results of head pocking test,cleft avoidance test,righting reflex test,negative 
geotaxis test and swimming rank test. While histopathological lesions  of brain may be due probable  penetration  
of  OP and/or OC cross BBB and cause damage to multiple areas of brain.The histopathological lesions reported 
in present  study were positively proportional to the OP doses even in the therapeutic dose may explain the 
proposed changes in CNS neurotransmitters levels and their consequence effect on the results of neurobehavioral 
tests  that done on pups directly dosed  with OP during lactating period that explain the  response effect 
according to increasing  doses. The present neurotoxic effects of neonates in dosed groups might considered 
early report to explain neurotoxic symptoms noticed in human neonates and children after administration of  the 
drug. 
 
Conclusion The prophylactic dose of 2.5mg/kg.BW for infants ,should be reviewed since it induces neurotoxic  
effect in lactating pups at age  (7-21 days postnatal) . 
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